ATCC ATCC Logo 0
  • Quick Order
  • Careers
  • Support

CAR-T Target Luciferase Reporter Cells

CAR-T cells, CAR-Target, CD19, CD20, HER2

Accelerating Your CAR-T Therapy Development

One of the bottlenecks in CAR-T therapeutic development is evaluating the biofunction of effector cells. This in vitro process involves a series of labor-intensive co-culture immunoassays. To address this challenge, we generated luciferase reporter cell lines that have high endogenous expression of clinically relevant cell surface tumor antigens such as CD19, CD20, and HER2. These new immuno-oncology tools include both solid and liquid tumor cell lines that exhibit sensitive and stable luciferase reporter expression. These cells enable your immuno-therapeutic breakthroughs by allowing you to monitor the potency and efficacy of candidate CAR-T effector cells in your cytotoxicity and cell viability assays in real time.

Table 1: CAR-T Target Luciferase Reporter Cells

Designation ATCC® No.Disease  Target
WIL2-S-Luc2  
 CRL-8885-LUC2™  B Cell Lymphoma CD19
 Raji-Luc2  CCL-86-LUC2 Burkitt’s Lymphoma CD19
 Daudi-Luc2 CCL-213-LUC2 Burkitt’s Lymphoma CD20
 Farage-Luc2 CRL-2630-LUC2 Non-Hodgkin’s B Cell Lymphoma CD20
 BT-474-Luc2 HTB-20-LUC2 Breast Ductal Carcinoma HER2

We are offering 10% off Checkpoint and CAR-T Target Reporter Models* Use promo code ATCC-000028 at checkout to take advantage of this special discount. This limited-time offer is effective from April 1 - May 15, 2024, so place your order before time runs out!

*Offer is effective from April 1st – May 15th, 2024. The 10% discount applies only to ATCC Checkpoint and CAR-T Target Reporter Models; all other items are excluded from this promotion. For non-profit customers, the promotional discount is applied to the customer-specific pricing. The promo code must be applied at the time of checkout. The promo code must be applied in the “Promotional code” field in the shopping cart. U.S. customers only. Void where prohibited. Restrictions may apply. Limit 20 vials.

These convenient reporter-labeled cells allow you to eliminate workflows involving radioactive or fluorescent dye labeling. The cells retain high expression of both the target antigen and luciferase up to 30 population doublings. These flexible target cells can also be incorporated in other immuno-oncology applications such as ADCC and natural killer (NK) cell cytotoxicity assays.

  • High expression stability of both target antigen and luciferase
  • High signal-to-noise ratio (S/N)
  • Physiologically relevant low E:T ratios
  • High-performing, fully authenticated cell lines
  • Easy-to-use reporter system
  • Real-time, live-cell imaging possible
 
 figure 1 neurosphere growth
CAR-T Target Luciferase Reporter Cells. Schematic showing CAR-T target cells with expression of CD19-positive WIL2-S-Luc2 and Raji-Luc2, CD20-positive Daudi-Luc2 and Farage-Luc2, and HER2-positive BT-474-Luc2 being surrounded and attacked by CD19-, CD20-, and HER2-targeting CAR-T cells, respectively. 

CAR-T Effector Cell Efficacy Using Raji-Luc2 and WIL2-S-Luc2

 Fig 2

CAR-T Target Luciferase Reporter Cells can be incorporated into multiple CAR-T efficacy assays. (A) CD19 expressing Raji-Luc2 cells (B) or WIL2-SLuc2 cells were used as target cells for either CD19 CAR-T or Mock CAR-T (control) effector cells from the same donor at the indicated effector to target cell ratios. A luciferase assay substrate was added, and the luminescence signal was detected. Loss of signal indicates cell death; the dose-dependent specific killing via CD19-targeting CAR-T cells was greater than the non-specific killing observed with the mock CAR-T cells. Additionally, Raji-Luc2 cells were stained with a cell labeling dye and then real-time fluorescent imaging was measured during co-culture with CD19 CAR-T effector cells. (C) Raji-Luc2 cells (Green) are surrounded by effector T cells, resulting in a decrease of fluorescence as compared to co-cultures with Mock-CAR-T cells. (D) After 6 and 24 hours of co-culture with CD19 CAR-T effector cells, we observed a decrease in the number of fluorescent cells; however, in a co-culture with Mock CAR-T cells numerous Raji-LUC2 cells were present. These results indicate that the ATCC CAR-T Target Luciferase Reporter Cells can be used to evaluate the potency of CAR-T cells in bioluminescence assays and live cell imaging in real time.

 

CAR-T Target Luciferase Reporter-labeled Cells

Webinar

In this webinar, we present new luciferase reporter tumor cell lines that naturally express clinically relevant CAR-T target antigens on cell surface such as CD19, CD20 and HER2. Watch the webinar to see how these versatile reporter lines can be utilized to examine the function of CAR-T cells.

View the webinar

Application Note

To provide target cells for immuno-oncology researchers, we generated CAR-T Target Luciferase Reporter Cells. Read the application note to learn how these highly authenticated cells can help provide increased reproducibility in your CAR-T effector potency experiments.

Read the app note

Refine by